Evaluation of vitamin D3 Supplementation on Serum Level of P-selectin and hs-CRP

Evaluation of vitamin D3 Supplementation on Serum Level of P-selectin and hs-CRP in Patients with Thrombosis, a Randimized Controled Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112068307N1

Enrollment

Registered

2012-06-12

Start date

2012-06-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis. Other venous embolism and thrombosis

Interventions

Intervention 1: Control group: is not given vitamin D 300000. Intervention 2: Intervention: Ampule Vitamin D3 300,000 IU intramuscle every one month.

Treatment - Drugs

Control group: is not given vitamin D 300000

Intervention: Ampule Vitamin D3 300,000 IU intramuscle every one month

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusin criteria : patients with confirmed thrombosis up to 1 months; patients with 18 years old and over and consented patients. Exclusion criteria: hypercalcemia, nephrolithiasis,Sarcoidosis, vitamin D supplementation,malabsorbtion syndrome, Severe infection, uncontrolled autoimmune and inflammatory diseases and pregnancy and any drugs, conditions and diseases that affect the P-selectin levels.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
25-hydroxy vitamin D3. Timepoint: before and 1 month after intervention. Method of measurement: Radioimmunoassay.	—

Primary

Measure	Time frame
P-selectin. Timepoint: before and 1 month after intervention. Method of measurement: ELAISA, lab.;Hs-CRP. Timepoint: before and 1 month after intervention. Method of measurement: ELAISA, lab.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026